Asylia Therapeutics is developing immune-modulating therapies for the treatment of autoimmune, cancer and infectious diseases. The fundamental mechanism of immunity is the presentation of antigens to the immune system. However, tumors use a variety of mechanisms to suppress a patient's immunity avoiding immune attack.  Asylia’s lead candidate, ASY-77A, enhances antigen presentation by targeting the extracellular form of the protein HSP70, a protein central to antigen delivery to the immune system. ASY-77A is an antibody product and has produced complete remission in preclinical models of various cancer types. Now Asylia is humanizing ASY-77A to initiate human safety and proof of concept trials.

Asylia Therapeutics

Short description:

Drug notes:

Long description:

Jobs: